Analysts’ average price target for Arcutis Biotherapeutics (ARQT) implies 25.8% upside. The article notes that price-target averages have not been reliably predictive, but emphasizes strong analyst agreement in raising earnings estimates as the key support for the bullish setup.
Analysts’ average price target for Arcutis Biotherapeutics (ARQT) implies 25.8% upside. The article notes that price-target averages have not been reliably predictive, but emphasizes strong analyst agreement in raising earnings estimates as the key support for the bullish setup.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
